PDCD1 and malignant epithelioid mesothelioma: The outcomes provide the robust foundation for the development of a RCT aimed at evaluating the comparative efficacy and toxicity of the combined anti-PD-1 and anti-TIGIT treatment to nivolumab and ipilimumab in patients with unresectable epithelioid mesothelioma.